CureVac N.V. and GSK entered into an agreement to resolve a patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines. As part of this settlement, GSK will receive an upfront payment of $370 million from CureVac.
GSK will also collect a 1% royalty on United States sales of Pfizer and BioNTech’s influenza, COVID-19, and related combination mRNA vaccines, effective from the start of 2025. The $370 million settlement includes $320 million in cash, with the remainder reflecting changes to GSK’s existing license agreement with CureVac.
Additionally, GSK may receive a further $130 million in cash and additional royalties if BioNTech's planned takeover of CureVac is completed, which would settle outstanding litigation outside the U.S. This agreement resolves a significant legal overhang for CureVac.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.